Update; Press on Feb 4 suggests the IPO is $150M. Here.
The COVID pandemic has seen enormous new investments in R&D, including for point of care tests. For example, I saw an advertisement for the NIH RADx-funded PCR device from VISBY a few weeks ago (here).
Here's a new one, where we have both some news reports and a full-length IPO document for LUCIRA, intended as a home-use POCT that uses LAMP amplification for very rapid COVID results.
Genomeweb - here - writes,
In November, the company received Emergency Use Authorization from the US Food and Drug Administration for the Lucira COVID-19 All-in-One Test Kit, a rapid, at-home, real-time loop-mediated isothermal amplification (LAMP) SARS-CoV-2 test available by prescription that runs on a handheld batter-powered device. An over-the-counter version of the test is expected to be submitted to the FDA later this year.
On the same theme of POCT COVID: see a (subscription) deep dive article at Genomeweb by Kelsy Ketchum on January 21, on the startup STARTUP DETECT, formerly HOMODEUS. Here.
Update: A few days after LUCIRA, the molecular microbiology firm TALIS also filed for an IPO - here.